Spravato Success Rate: How Well Does Esketamine Work?

If you are considering Spravato (esketamine) for depression that has not improved on other treatments, the first question is almost always the same: does it actually work? The honest answer is that Spravato helps a meaningful share of people who have run out of options — but the success figures you see online swing from a cautious 40% to a dramatic 88%, and that range is exactly where most articles mislead you.

Here is what the research actually shows. In clinical trials, Spravato produces a response in roughly 50–70% of patients and full remission in about 30–50% when added to an oral antidepressant — outcomes achieved in people who had already failed two or more medications. Real-world clinics, treating less tightly selected patients, often report response or improvement in 60–80% of cases. The numbers jump around so much because “success” is defined in different ways, in different patients, measured at different points in time. Once you understand those distinctions, the data becomes far more useful for making a decision.

What “Success” Actually Means for Spravato

Before comparing any percentage, you have to know what is being counted. Researchers measure depression with standardized scales — most often the Montgomery-Åsberg Depression Rating Scale (MADRS, scored 0–60) or the PHQ-9 (scored 0–27) — and three terms do most of the work. They are not interchangeable:

• Response means a clinically significant improvement — usually at least a 50% drop in depression symptom scores. Someone who responds feels substantially better but may still have some symptoms. In Spravato trials, roughly 50–70% of patients reach this bar.
• Remission is the higher bar: symptoms fall low enough (for example, MADRS ≤10) that the person no longer meets the criteria for depression. This is the outcome most patients are actually hoping for. Studies put Spravato remission at about 30–50% during the acute phase.
• Relapse tracks the other direction — how many people whose symptoms return after a period of improvement. It is the key measure of how durable the benefit is, and it is where maintenance treatment earns its place.

When a clinic advertises an “80% success rate,” it is almost always quoting a response rate, not remission. Neither number is wrong, but they describe very different results. Throughout this article we separate the two so you can compare like with like.

Spravato Success Rate in Clinical Trials

The most rigorous evidence comes from the Phase 3 TRANSFORM trials, which led to Spravato’s FDA approval for treatment-resistant depression in 2019. In these studies, patients added either esketamine nasal spray or a placebo spray to a newly started oral antidepressant.

• TRANSFORM-2, the pivotal positive trial, reported a response rate of about 69% in the esketamine group versus 52% on antidepressant plus placebo by day 28, with a clinically meaningful improvement on the MADRS.
• TRANSFORM-1 showed a similar direction — roughly 53% response with esketamine versus 31% with placebo — though the gap did not reach statistical significance on its primary endpoint, a nuance honest summaries should include.

The pattern across the program is consistent: adding Spravato roughly 15–20 percentage points to the response rate compared with an antidepressant alone. For a population that, by definition, had already failed multiple medications, that is a substantial difference — not a miracle, but a real one.

Real-World Success Rates: Beyond the Trials

Clinical trials run under tightly controlled conditions. Real-world data — drawn from ordinary clinics treating ordinary patients — paints a fuller picture, and it is often more encouraging than the trial figures.

Observational studies and treatment registries have reported clinically significant improvement in roughly 60–80% of patients across several treatment cycles, with the higher figures usually coming from patients who stay in treatment through the maintenance phase. One widely cited real-world analysis found that about 88% of patients were rated “much improved” or “very much improved” within the first three months, and that a majority of those gains were still present two years later.

Two cautions keep this honest. Real-world numbers look higher partly because they often count “completers” — people who stuck with treatment — rather than everyone who started. And open-label clinics, unlike blinded trials, have no placebo arm to subtract. The takeaway is not that one set of numbers is fake, but that the truth sits in the overlap: most people who complete a proper course of Spravato experience meaningful relief, and a substantial minority reach full remission.

How Fast Does Spravato Work?

Speed is where Spravato genuinely stands apart. Traditional antidepressants typically take four to six weeks to produce a noticeable effect. Spravato can work far faster: in controlled studies, some patients improved within 24 to 48 hours of the first dose, and a measurable separation from placebo was often visible by 24 hours.

That rapid action is one reason esketamine was also approved for major depressive disorder with acute suicidal ideation — when a person is in crisis, waiting weeks for an SSRI to take hold is not a safe option. It is worth being clear-eyed, though: a fast first response is not the same as a lasting one. Early improvement still has to be consolidated with a full course of treatment, which is exactly what the trial schedules are designed to do. If you want the mechanism behind the speed, our explainer on how Spravato differs from traditional antidepressants breaks it down.

Does the Benefit Last? Maintenance and Relapse

A high response rate means little if the benefit disappears in a month, so durability is the question that matters most. Here the evidence is reassuring, with an asterisk: the benefit tends to last as long as treatment continues.

The landmark relapse-prevention trial (SUSTAIN-1) found that patients who achieved a stable response or remission and then continued esketamine were markedly less likely to relapse than those switched to placebo — roughly a 50% lower relapse risk in stable remitters, and an even larger reduction in stable responders. Long-term maintenance studies have reported remission sustained in the region of 46% of patients at the end of the optimization and maintenance phase, and that about 60–70% of initial responders hold onto their gains with continued dosing.

The practical implication is important. Spravato is generally not a one-time cure; it is a treatment that produces relief which is then maintained, usually with dosing that tapers from twice weekly to once weekly or every other week. This is also where it differs from TMS, whose benefits tend to outlast the treatment course itself, and from IV ketamine, whose effects can fade within days of stopping.

Success Rate for Treatment-Resistant Depression and Suicidal Depression

Spravato is not a general-purpose antidepressant. In the United States it is approved specifically for two situations, and the success data should be read in that context.

For treatment-resistant depression (TRD) — depression that has not responded to at least two adequate antidepressant trials — the evidence consistently shows that more than half of patients improve significantly when Spravato is added to their regimen. Because TRD is, by definition, the hardest depression to treat, even a 50–60% response rate represents a major clinical win for a group that had largely stopped responding to medication. If you are not sure whether you fit this picture, our guide on how to know if you have treatment-resistant depression is a good starting point.

For major depressive disorder with acute suicidal ideation or behavior, the ASPIRE trials showed that esketamine plus standard care reduced depressive symptoms rapidly, within the first 24 hours, compared with standard care alone. The goal in that setting is somewhat different — fast stabilization during a dangerous window — but the rapid-response data again held up.

What Affects Your Spravato Success Rate

Population averages only tell you so much. Several factors shift the odds for any individual patient, and a few of them are within your control:

• Adherence to the schedule. This is the big one. Patients who complete the recommended eight induction sessions in the first month respond at far higher rates — in some analyses around 73% — than those who miss sessions and drift out of the protocol. Spravato rewards consistency.
• Pairing it with therapy and the right medication. Outcomes tend to be better when Spravato is combined with ongoing psychotherapy and a well-chosen oral antidepressant rather than used in isolation. It works best as part of a plan, not as a standalone fix.
• Realistic expectations. Patients who understand that some people improve in days while others need several weeks are more likely to stay the course long enough to benefit. Early disappointment is a common — and avoidable — reason people quit too soon.
• Co-occurring conditions. Significant co-occurring anxiety can modestly lower response rates, though many patients with anxious depression still benefit. A careful psychiatric evaluation helps set the right plan.
• Measurement-based care. Practices that track your scores at each visit can tell early whether it is working and adjust before momentum is lost — which is part of what separates a strong real-world success rate from a disappointing one.

The Honest Limitations

A fair account of Spravato’s success rate has to include the people it does not help. Across studies, roughly 25–35% of patients do not respond adequately even after a proper trial, and a smaller group respond at first and then lose ground before regaining it with dose adjustments. Spravato is powerful, but it is not universal.

There are practical hurdles too. Because of the required monitoring, every dose is given in a certified clinic with a two-hour observation period, and you cannot drive yourself home afterward — we explain why in our overview of the Spravato REMS program. In trials, 12–18% of patients discontinued because of side effects such as dissociation, dizziness, nausea, or sedation, and in the real world, scheduling, transportation, and cost or insurance barriers cause some eligible patients never to start or to stop early — often for logistical reasons rather than lack of effectiveness. None of this makes the treatment less effective for those who complete it, but it is part of an honest success-rate conversation.

How Spravato Compares to Other Options

Success rates only mean something in context. For depression that is not improving, Spravato is one of several advanced options, and the right choice depends on the person:

• Antidepressant medication. First-line antidepressants help many people, but their returns fall sharply with each failed trial — after several failures, the odds from yet another pill drop to roughly a third. That is precisely the point at which Spravato becomes a logical next step.
• TMS. Transcranial magnetic stimulation is slower to act but its benefits tend to be durable. Our companion piece on the TMS success rate lays out the 50–60% response and 30–40% remission figures so you can compare them side by side.
• IV and IM ketamine. These act on the same glutamate system and work quickly, but are off-label for depression and not insurance-covered the way Spravato often is. We compare all three in Spravato vs. IV ketamine vs. IM ketamine.

These options are not mutually exclusive. Many patients move between or combine them over time, and the best sequence is a clinical decision, not a number on a webpage.

Spravato at Bright Horizons Psychiatry in Maryland

At Bright Horizons Psychiatry in Rockville, MD — and now in Frederick — we are a REMS-certified Spravato provider focused on exactly the kind of complex, treatment-resistant depression where esketamine does its best work. Just as important, we practice measurement-based care: we track your symptoms at each visit so we can tell early whether Spravato is working and adjust the plan when it is not. As the research makes clear, that approach is part of what turns an average outcome into a strong one.

Whether Spravato is right for you depends on your history, your diagnosis, and your goals — none of which a percentage can answer. The next step is a real evaluation with a psychiatrist who can tell you, candidly, what your odds look like.

Frequently Asked Questions

Medical disclaimer: This article is for general educational purposes and is not medical advice. Success rates are population averages drawn from published research and may not reflect individual results. Always consult a qualified psychiatrist about your specific situation before making treatment decisions.

Key sources: Popova et al., TRANSFORM-2 (American Journal of Psychiatry, 2019); Fedgchin et al., TRANSFORM-1 (2019); Daly et al., SUSTAIN-1 relapse-prevention trial (JAMA Psychiatry, 2019); long-term maintenance-of-response analyses of esketamine (e.g., Zaki et al., 2023); Ionescu et al. and Fu et al., ASPIRE trials (2020); Janssen/Johnson & Johnson real-world evidence for SPRAVATO; U.S. FDA SPRAVATO prescribing information.